User talk:EGagnon7224/Sandbox

Notability:

(1) Onyx is a publicly traded biopharmaceutical company on NASDAQ under ONXX--http://finance.yahoo.com/q?s=ONXX.

(2) Onyx's profile on Hoover's: http://www.hoovers.com/onyx-pharmaceuticals/--ID__51415--/free-co-factsheet.xhtml.

(4) Recent analyst coverage of Onyx can be found here: http://finance.yahoo.com/q/ao?s=ONXX

(5) Onyx has receives regular media coverage from wires and top business outlets, some recent examples follow

- Gryta, Thomas. "Onyx Pharma Building Product Pipeline In Opportune Environment." Dow Jones. 26 March 2009.

- Chase, Marilyn and Dooren, Jennifer Corbett. "New Drugs Show Promise for Liver Cancer."  The Wall Street Journal. 5 June 2007.

- http://www.bizjournals.com/sanfrancisco/stories/2008/07/21/story1.html

- http://finance.yahoo.com/news/Onyx-shares-rise-on-4Q-apf-14459115.html?.v=2

- http://www.fool.com/investing/high-growth/2009/02/24/5-stocks-approaching-greatness.aspx

(6) To view Onyx's 2008 annual report: http://www.onyx-pharm.com/pdf/Onyx_AR08.pdf



Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), headquartered in Emeryville, California, is a biopharmaceutical company developing therapeutic drugs for cancer. It was established in The President and CEO is N. Anthony (Tony) Coles, M.D.;  Paul Goddard, Ph.D. is chairman of the Board of Directors.

Products
Onyx’s lead product is Nexavar (sorafenib). an oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. The product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 70 countries for treatment of advanced renal cell carcinoma, and in more than 60 countries for treatment of hepatocellular carcinoma. It is being evaluated in Phase 3 and Phase 2 trials for other cancers, alone or as part of combination therapy with other agents.

There are several other products in development. In November 2008, Onyx in-licensed a targeted anticancer agent called ONX 0801 (formerly BCG 945) from BTG International Ltd. This compound targets malignant cells that over-express the surface alpha-folate receptor. Once ONX 0801 enters the cell via this receptor, it inhibits thymidylate synthase (TS), a key enzyme in cell growth and division. This is distinct from currently marketed TS inhibitors for its selective tumor cell-specific uptake by the alpha-folate receptor.

In December 2008, Onyx acquired license options to two inhibitors of Janus Kinase 2 (JAK2) from S*BIO Pte. Ltd. The first, ONX 0803 (formerly SB1518), suppress overactivity of mutant JAK2 and is currently in Phase 1 studies for primary myelofibrosis. ONX 0805 (formerly SB1578), the second compound, is still in preclinical development.

In addition, PD 332991, an small molecule CDK4 inhibitor, entered clinical testing in 2004 as a result of a collaboration with Warner-Lambert Company, now Pfizer. This compound  intervenes in the misregulated cell cycle of tumor cells by inhibiting a key enzyme, cyclin-dependent kinase 4 (cdk4).